A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Pancreatic Cancer|Hepatocellular Cancer|Mesothelioma|Breast Cancer|Gastric Cancer|Esophageal Cancer|Nasopharyngeal Cancer|Kidney Cancer|Squamous Cell Cancer of Head and Neck (SCCHN)|Non-small Cell Lung Cancer (NSCLC), Non-squamous
Interventions: DRUG: TAK-500|DRUG: Pembrolizumab
Sponsor: Takeda